Wield Therapeutics is focused on developing treatments for autoimmune diseases by addressing the root causes of inflammation to induce durable, drug-free remissions. Our programs are rooted in strong human genetic validation, increasing the probability of clinical success by 2-3x. We connect networks of associations in genetic and multi-omic data and use them to identify targets involved in autoimmune disease. The heterogeneity of autoimmune diseases means that effective drugs can be missed when patients are not diagnosed with the molecular pathways driving their disease. Our approach identifies patients most likely to respond to our therapeutics. This allows for smaller, faster, and more efficient clinical trials, and increases the probability of clinical success by tooling the statistical analyses to evaluate rapid efficacy.